Compile Data Set for Download or QSAR
maximum 50k data
Found 349 with Last Name = 'bergnes' and Initial = 'g'
TargetCreatine kinase M-type(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50291548(CHEMBL8056 | Phosphocreatine analogue)
Affinity DataKi:  1.40E+6nMAssay Description:Compound was tested for inhibition against Creatine kinase (CK)More data for this Ligand-Target Pair
In DepthDetails Article
TargetCreatine kinase M-type(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50291549(CHEMBL8265 | Phosphocreatine analogue)
Affinity DataKi:  5.70E+6nMAssay Description:Compound was tested for inhibition against Creatine kinase(CK)More data for this Ligand-Target Pair
In DepthDetails Article
TargetCreatine kinase M-type(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50291547(CHEMBL8013 | Phosphocreatine analogue)
Affinity DataKi:  3.70E+7nMAssay Description:Compound was tested for inhibition against Creatine kinase (CK)More data for this Ligand-Target Pair
In DepthDetails Article
LigandPNGBDBM50128463((S)-2-{[1-((R)-2-Amino-3-mercapto-propionyl)-4-phe...)
Affinity DataIC50: <5nMAssay Description:Inhibition of Candida albicans Geranylgeranyl transferase type IMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50128465((S)-2-{[1-((R)-2-Amino-3-mercapto-propionyl)-4-phe...)
Affinity DataIC50:  5nMAssay Description:Inhibition of Candida albicans Geranylgeranyl transferase type IMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50128464((S)-2-((S)-2-{[1-((R)-2-Amino-3-mercapto-propionyl...)
Affinity DataIC50:  10nMAssay Description:Inhibition of Candida albicans Geranylgeranyl transferase type IMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636506(US20230365556, Compound 121)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636507(US20230365556, Compound 122)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448836(US10696672, Compound 68 | US11634418, Compound 68)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448838(US10696672, Compound 70 | US11634418, Compound 70)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448839(US10696672, Compound 71 | US11634418, Compound 71)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448840(US10696672, Compound 72 | US11634418, Compound 72)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448841(US10696672, Compound 73 | US11634418, Compound 73)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448842(US10696672, Compound 74 | US11634418, Compound 74)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448843(US10696672, Compound 75 | US11634418, Compound 75)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448844(US10696672, Compound 76 | US11634418, Compound 76)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448845(US10696672, Compound 77 | US11634418, Compound 77)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448846(US10696672, Compound 78 | US11634418, Compound 78)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448847(US10696672, Compound 79 | US11634418, Compound 79)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448848(US10696672, Compound 80 | US11634418, Compound 80)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448850(US10696672, Compound 82 | US11634418, Compound 82)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448851(US10696672, Compound 83 | US11634418, Compound 83)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448852(US10696672, Compound 84 | US11634418, Compound 84)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448853(US10696672, Compound 85 | US11634418, Compound 85)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448854(US10696672, Compound 86 | US11634418, Compound 86)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448855(US10696672, Compound 87 | US11634418, Compound 87)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448856(US10696672, Compound 88 | US11634418, Compound 88)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448857(US10696672, Compound 89 | US11634418, Compound 89)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448858(US10696672, Compound 90 | US11634418, Compound 90)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448860(US10696672, Compound 92 | US11634418, Compound 92)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448863(US10696672, Compound 95 | US11634418, Compound 95)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448867(US10696672, Compound 99 | US11634418, Compound 99)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448871(US10696672, Compound 103 | US11634418, Compound 10...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448872(US10696672, Compound 104 | US11634418, Compound 10...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448874(US10696672, Compound 106 | US11634418, Compound 10...)
Affinity DataIC50:  50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448875(US10696672, Compound 107 | US11634418, Compound 10...)
Affinity DataIC50:  50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448878(US10696672, Compound 110 | US11634418, Compound 11...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448883(US10696672, Compound 115 | US11634418, Compound 11...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448891(US10696672, Compound 123 | US11634418, Compound 12...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448895(US10696672, Compound 127 | US11634418, Compound 12...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM601587(US11634418, Compound 141)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448914(US10696672, Compound 146 | US11634418, Compound 14...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C. overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636488(2-(2,6-dichlorobenzamido)-9-(5,6,7,8- tetrahydro-1...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636490(2-(1-methyl-1H-indazole-6- carboxamido)-9-(5,6,7,8...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636491(US20230365556, Compound 87)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636493(US20230365556, Compound 88)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636494(US20230365556, Compound 89)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636495(US20230365556, Compound 90)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636496(US20230365556, Compound 91)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM636497(US20230365556, Compound 92)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 349 total ) | Next | Last >>
Jump to: